PubMed

Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.

Dalla Man C, Bock G, Giesler PD, Serra DB, Ligueros Saylan M, Foley JE, Camilleri M, Toffolo G, Cobelli C, Rizza RA, Vella A.

Diabetes Care. 2009 Jan;32(1):14-8. Epub 2008 Oct 17.PMID: 18931099 [PubMed - in process]Related articlesFree article

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE.

Diabetes Care. 2008 Jan;31(1):108-13. Epub 2007 Oct 1.PMID: 17909087 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

Ahrén B, Pacini G, Foley JE, Schweizer A.

Diabetes Care. 2005 Aug;28(8):1936-40.PMID: 16043735 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M.

Diabetes. 2007 May;56(5):1475-80. Epub 2007 Feb 15.PMID: 17303799 [PubMed - indexed for MEDLINE]Related articlesFree article

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE.

J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. Epub 2007 Nov 27.PMID: 18042650 [PubMed - indexed for MEDLINE]Related articlesFree article

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA.

J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23.PMID: 17244786 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Deacon CF, Foley JE, Rizza RA, Camilleri M.

Clin Endocrinol (Oxf). 2008 Nov;69(5):737-44. Epub 2008 Mar 10.PMID: 18331607 [PubMed - indexed for MEDLINE]Related articles

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.

Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang X, Duttaroy A, Cherrington AD.

Diabetes. 2009 Jan;58(1):243-9. Epub 2008 Oct 7.PMID: 18840785 [PubMed - indexed for MEDLINE]Related articlesFree article

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE.

J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94. Epub 2005 May 10.PMID: 15886245 [PubMed - indexed for MEDLINE]Related articlesFree article

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR.

Diabetologia. 2006 Sep;49(9):2049-57. Epub 2006 Jul 1.PMID: 16816950 [PubMed - indexed for MEDLINE]Related articles

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA.

J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71. Epub 2007 Aug 14.PMID: 17698900 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.

Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G.

Diabetes Care. 2003 Feb;26(2):421-6.PMID: 12547873 [PubMed - indexed for MEDLINE]Related articlesFree article

Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

Diabetes Care. 2002 Dec;25(12):2147-52.PMID: 12453952 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.

Greenbaum CJ, Prigeon RL, D'Alessio DA.

Diabetes. 2002 Apr;51(4):951-7.PMID: 11916912 [PubMed - indexed for MEDLINE]Related articlesFree article

beta-Cell function and insulin sensitivity in adolescents from an OGTT.

Sunehag AL, Man CD, Toffolo G, Haymond MW, Bier DM, Cobelli C.

Obesity (Silver Spring). 2009 Feb;17(2):233-9. Epub 2008 Dec 4.PMID: 19057529 [PubMed - indexed for MEDLINE]Related articles

Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.

Shapiro ET, Van Cauter E, Tillil H, Given BD, Hirsch L, Beebe C, Rubenstein AH, Polonsky KS.

J Clin Endocrinol Metab. 1989 Sep;69(3):571-6.PMID: 2503533 [PubMed - indexed for MEDLINE]Related articles